Collaborations, Alliances and License Agreements

• Spero Therapeutics in its license agreement with GSK to develop and commercialize tebipenem HBr, Spero’s late stage antibiotic to treat cUTI
• Spero Therapeutics in its collaboration with Pfizer Inc to develop and commercialize SPR206, an IV-administered gram negative antibiotic product candidate outside of the US, Greater China, South Korea, and certain Southeast Asian countries
• Spero Therapeutics in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop Spero’s orally administered SPR720 for the treatment of tuberculosis 
• Synlogic in its $80M equity investment at a premium from Ginkgo Bioworks and entry into a long-term strategic platform collaboration 
• Aura Biosciences in its license agreement with Clearside Biomedical for suprachoroidal delivery of AU-011
• DNAtrix in its collaboration with Valo Therapeutics to develop “armed” oncolytic vaccines for cancer therapy using DNAtrix’s clinical stage oncolytic viruses 
• Spero Therapeutics in its collaboration with Everest Medicines to develop and commercialize SPR206 , an IV-administered gram negative antibiotic product candidate in Greater China, South Korea, and certain Southeast Asian countries
• Synlogic in its global R&D collaboration with AbbVie to develop novel synthetic medicines to treat inflammatory bowel disease
• Spero Therapeutics in its license with Meiji Pharmaceuticals, its acquisition of worldwide rights to VXc-486/VXc-100 antibacterial compounds from Vertex Pharmaceuticals, and its acquisition of next generation antibacterial candidates from Pro Bono Bio Ltd
• Macrolide Pharmaceuticals in its agreement with Cempra to develop a synthetic manufacturing  process for solithromycin
• Biogen Idec in its collaboration with Ataxion to develop drugs to treat hereditary ataxias
• Amorsa Therapeutics in its research, option and license agreement with Janssen Pharmaceuticals, to develop novel ketamine-derived drugs for treatment-resistant depression
• Paratek Pharmaceuticals in its $485M global collaboration with Novartis
• Numerous foundational in-licenses from leading universities, hospitals and institutions, including Harvard, MIT, Boston University, Case Western, Michigan, Einstein College, MGH, Tufts, University of Florida, others

Venture Capital Financings

• Triana Biomedicines in its launch with $110M from RA Capital, Atlas Ventures, Lightspeed Ventures, Pfizer Ventures and others
• CAM Capital in its investments in Primmune and Arcellx
• A Fortune 500 healthcare company in numerous venture investments
• Santi Therapeutics, Avilar Therapeutics, Athenen Therapeutics, Arcuate Therapeutics and Nayan Therapeutics, recently launched companies incubated by RA Capital, in each of their inaugural financings from RA Capital affiliates  
• Aura Biosciences in its $30M and $40M financings to advance the clinical development of its Ocular Melanoma treatment
• Sofinnova Ventures, Ysios Capital, INKEF Capital and Sectoral Asset Management in $30M and $50M investments in Ranier Therapeutics (formerly BioClin Therapeutics)
• Spero Therapeutics in its $51.7M financing to advance its pipeline of antibacterials focused on drug-resistant bacterial infections
• Synlogic in its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
• Macrolide Pharmaceuticals in its $22M Series A financing to develop novel antibiotics
• Opsonix in its $8M Series A financing to develop a broad spectrum pathogen-extracting therapy
• Venture investors in the $21M Series B financing of Aura Biosciences, to treat ocular melanoma
• RA Capital in numerous venture financings, including Ventus Therapeutics, Quench Bio, Arvinas, Cidara Therapeutics, G1 Therapeutics and White Swell Medical
• MVM Life Science Partners in numerous venture financings, including AccuVein, BioTheranostics, Zipline Medical, Cheetah Medical and Solx
• Merck Research and Licensing (MRL) Ventures in several financings, including RaNA Therapeutics and miRagen Therapeutics

M&A and Public Offerings

• Amorsa Therapeutics in its acquisition by an undisclosed publicly traded CNS biopharma company on undisclosed terms
• Spero Therapeutics in its $88M Initial Public Offering, $75M follow-on public offering and $10M Registered Direct Offering 
• Synlogic in its IPO by way of a reverse merger with Mirna Therapeutics, Inc.
• Synlogic in its $50M follow-on public offering
• AFT Pharmaceuticals in its $33M Initial Public Offering
• Beacon Endoscopic in its sale to Covidien